Claims that tranexamic acid (TXA) should not be used to prevent life-threatening bleeding after childbirth have been challenged by researchers from the London School of Hygiene & Tropical Medicine (LSHTM), who argue that the evidence supports its use in countries with a high risk of maternal death.
In a letter titled “The role of tranexamic acid in reducing maternal death”, published in The Lancet, the researchers respond to a recent paper in the same journal on the prevention of postpartum haemorrhage (PPH).
PPH is reported as the leading cause of maternal death worldwide. Tranexamic acid works by helping blood clots remain intact. The drug is already recommended for treating PPH and is most effective when given as soon as possible after bleeding begins.
The Lancet paper, led by Dr Ioannis Gallos, a Medical Officer at the World Health Organization’s Maternal and Perinatal Health Unit, presented a broad strategy for preventing PPH, including addressing anaemia, improving access to contraception and antenatal care, reducing medically unnecessary caesarean births, and routinely providing uterotonic medicines after childbirth. It concluded that TXA does not have a preventive role, citing concerns about possible thromboembolic complications and medication errors.
In their response, the LSHTM researchers – Professor Ian Roberts, and Judith Lieber and Katharine Ker, both Assistant Professors – argue that this conclusion does not reflect the full body of evidence. They highlight an individual patient data (IDP) meta-analysis of several trials and over 50,000 women which found that TXA reduced life-threatening bleeding by approximately 25%.
The letter also points to a 2026 modelling and cost-effectiveness study which concluded that giving TXA to all women during childbirth could reduce maternal deaths in countries where at least five women per 100,000 births die from bleeding. According to the researchers, this threshold is exceeded in 116 countries, which together account for 86% of births worldwide.
Roberts, Lieber and Ker also challenge concerns that the drug increases dangerous blood clots. They note that studies involving tens of thousands of patients have found no evidence of an increased risk of thrombosis, although they acknowledge that a small increase cannot be completely ruled out. However, even TXA did increase the risk of thrombosis, there would still be a net mortality benefit in many countries.
They argue that decisions about preventive use should reflect the level of maternal risk in different settings. In countries where deaths from bleeding are more common, waiting until life-threatening bleeding develops may mean missing an important opportunity to save lives.
“Tranexamic acid is the only proven life-saving intervention for bleeding after childbirth,” the letter concludes. “Women should not be denied its benefits.”
Publication
Judith Lieber, Katharine Ker, Ian Roberts. Evidence and gaps for preventing postpartum haemorrhage. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(26)01820-9